117 related articles for article (PubMed ID: 28669560)
1. Potential of RASSF1A promoter methylation as biomarker for endometrial cancer: A systematic review and meta-analysis.
Pabalan N; Kunjantarachot A; Ruangpratheep C; Jarjanazi H; Christofolini DM; Barbosa CP; Bianco B
Gynecol Oncol; 2017 Sep; 146(3):603-608. PubMed ID: 28669560
[TBL] [Abstract][Full Text] [Related]
2. Promoter hypermethylation of the tumor-suppressor genes RASSF1A, GSTP1 and CDH1 in endometrial cancer.
Fiolka R; Zubor P; Janusicova V; Visnovsky J; Mendelova A; Kajo K; Lasabova Z; Plank L; Danko J
Oncol Rep; 2013 Dec; 30(6):2878-86. PubMed ID: 24068440
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic value of RASSF1A hypermethylation in colorectal cancer: a meta-analysis.
Hu H; Zhou C; Li B; Chen Y; Dai J; Mao Y; Huang T; Yu H; Chen M; Zhao J; Duan S
Pathol Res Pract; 2018 Oct; 214(10):1572-1578. PubMed ID: 30082160
[TBL] [Abstract][Full Text] [Related]
4. RASSF1A methylation and K-ras and B-raf mutations and recurrent endometrial cancer.
Pijnenborg JM; Dam-de Veen GC; Kisters N; Delvoux B; van Engeland M; Herman JG; Groothuis PG
Ann Oncol; 2007 Mar; 18(3):491-7. PubMed ID: 17170014
[TBL] [Abstract][Full Text] [Related]
5. Association between RASSF1A promoter methylation and renal cell cancer susceptibility: a meta-analysis.
Huang YQ; Guan H; Liu CH; Liu DC; Xu B; Jiang L; Lin ZX; Chen M
Genet Mol Res; 2016 Apr; 15(2):. PubMed ID: 27173228
[TBL] [Abstract][Full Text] [Related]
6. Potential of RASSF1A promoter methylation as a biomarker for colorectal cancer: Meta-analysis and TCGA analysis.
Hu F; Chen L; Bi MY; Zheng L; He JX; Huang YZ; Zhang Y; Zhang XL; Guo Q; Luo Y; Tang WR; Sheng MM
Pathol Res Pract; 2020 Aug; 216(8):153009. PubMed ID: 32703486
[TBL] [Abstract][Full Text] [Related]
7. Relationship between RAS Association Domain Family Protein 1A Promoter Methylation and the Clinicopathological Characteristics in Patients with Ovarian Cancer: A Systematic Meta-Analysis.
Wang H; Cui M; Zhang S; He J; Song L; Chen Y
Gynecol Obstet Invest; 2018; 83(4):349-357. PubMed ID: 29130987
[TBL] [Abstract][Full Text] [Related]
8. RASSF1A hypermethylation and its inverse correlation with BRAF and/or KRAS mutations in MSI-associated endometrial carcinoma.
Kang S; Lee JM; Jeon ES; Lee S; Kim H; Kim HS; Seo SS; Park SY; Sidransky D; Dong SM
Int J Cancer; 2006 Sep; 119(6):1316-21. PubMed ID: 16619251
[TBL] [Abstract][Full Text] [Related]
9. Associations between RASSF1A promoter methylation and NSCLC: a meta-analysis of published data.
Liu WJ; Tan XH; Guo BP; Ke Q; Sun J; Cen H
Asian Pac J Cancer Prev; 2013; 14(6):3719-24. PubMed ID: 23886171
[TBL] [Abstract][Full Text] [Related]
10. Promoter hypermethylation and reduced expression of RASSF1A are frequent molecular alterations of endometrial carcinoma.
Pallarés J; Velasco A; Eritja N; Santacana M; Dolcet X; Cuatrecasas M; Palomar-Asenjo V; Catasús L; Prat J; Matias-Guiu X
Mod Pathol; 2008 Jun; 21(6):691-9. PubMed ID: 18469797
[TBL] [Abstract][Full Text] [Related]
11. The relationship between RASSF1A promoter methylation and thyroid carcinoma: A meta-analysis of 14 articles and a bioinformatics of 2 databases (PRISMA).
Niu H; Yang J; Yang K; Huang Y
Medicine (Baltimore); 2017 Nov; 96(46):e8630. PubMed ID: 29145283
[TBL] [Abstract][Full Text] [Related]
12. [Meta-analysis of the Association between RASSF1A Gene Promoter Methylation and Non-small Cell Lung Cancer].
Wei H; Fang N; Guo L; Wu Z; Zhou Q
Zhongguo Fei Ai Za Zhi; 2015 Jul; 18(7):443-50. PubMed ID: 26182870
[TBL] [Abstract][Full Text] [Related]
13. Aberrant Methylation of RASSF1A Closely Associated with HNSCC, a Meta-Analysis.
Meng RW; Li YC; Chen X; Huang YX; Shi H; Du DD; Niu X; Lu C; Lu MX
Sci Rep; 2016 Feb; 6():20756. PubMed ID: 26857374
[TBL] [Abstract][Full Text] [Related]
14. Hypermethylation of RAS effector related genes and DNA methyltransferase 1 expression in endometrial carcinogenesis.
Liao X; Siu MK; Chan KY; Wong ES; Ngan HY; Chan QK; Li AS; Khoo US; Cheung AN
Int J Cancer; 2008 Jul; 123(2):296-302. PubMed ID: 18404674
[TBL] [Abstract][Full Text] [Related]
15. Association between RASSF1A promoter methylation and ovarian cancer: a meta-analysis.
Shi H; Li Y; Wang X; Lu C; Yang L; Gu C; Xiong J; Huang Y; Wang S; Lu M
PLoS One; 2013; 8(10):e76787. PubMed ID: 24116157
[TBL] [Abstract][Full Text] [Related]
16. Quantitative assessment of the relationship between RASSF1A gene promoter methylation and bladder cancer (PRISMA).
Zhan L; Zhang B; Tan Y; Yang C; Huang C; Wu Q; Zhang Y; Chen X; Zhou M; Shu A
Medicine (Baltimore); 2017 Feb; 96(7):e6097. PubMed ID: 28207521
[TBL] [Abstract][Full Text] [Related]
17. The relationship between RASSF1A gene promoter methylation and the susceptibility and prognosis of melanoma: A meta-analysis and bioinformatics.
Shao C; Dai W; Li H; Tang W; Jia S; Wu X; Luo Y
PLoS One; 2017; 12(2):e0171676. PubMed ID: 28207831
[TBL] [Abstract][Full Text] [Related]
18. Association between RASSF1A promoter methylation and prostate cancer: a systematic review and meta-analysis.
Pan J; Chen J; Zhang B; Chen X; Huang B; Zhuang J; Mo C; Qiu S
PLoS One; 2013; 8(9):e75283. PubMed ID: 24073258
[TBL] [Abstract][Full Text] [Related]
19. RASSF1A promoter methylation is associated with increased risk of thyroid cancer: a meta-analysis.
Shou F; Xu F; Li G; Zhao Z; Mao Y; Yang F; Wang H; Guo H
Onco Targets Ther; 2017; 10():247-257. PubMed ID: 28123306
[TBL] [Abstract][Full Text] [Related]
20. Association between HIC1 and RASSF1A promoter hypermethylation with MTHFD1 G1958A polymorphism and clinicopathological features of breast cancer in Iranian patients.
Rasti M; Tavasoli P; Monabati A; Entezam M
Iran Biomed J; 2009 Oct; 13(4):199-206. PubMed ID: 19946345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
